Eravacycline - Tetraphase Pharmaceuticals

Drug Profile

Eravacycline - Tetraphase Pharmaceuticals

Alternative Names: TP-434

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Acetamides; Antibacterials; Pyrrolidines; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Intra-abdominal infections
  • Phase III Urinary tract infections
  • Phase I Respiratory tract infections

Most Recent Events

  • 04 Oct 2017 Pharmacokinetics and adverse events data from a phase I trial in healthy volunteers released by Tetraphase Pharmaceuticals
  • 04 Oct 2017 Tetraphase Pharmaceuticals plans a phase II trial for urinary tract infections (PO) in the first half of 2018
  • 11 Sep 2017 Tetraphase Pharmaceuticals completes the phase III IGNITE4 trial in Intra-abdominal infections in Bulgaria, Romania, Georgia, Russia, Ukraine, Hungary, Czech Republic, Latvia, Estonia, Lithuania, USA (IV) (NCT02784704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top